Acuta Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History

Acuta Capital Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-42,000	Closed	-$1.91M	–	73
2016 Q2	$1.91M	Buy	+42,000	New	+$1.93M	0.92%	31
2016 Q1	–	Sell	-56,000	Closed	-$3.17M	–	45
2015 Q4	$3.17M	Buy	+56,000	New	+$2.85M	1.52%	21

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Acuta Capital Partners's NBIX Position: Q3 2016 in Review

Acuta Capital Partners sold out of Neurocrine Biosciences (NBIX) in Q3 2016, closing a stake of 42,000 shares — an estimated $1.91M sold.

Acuta Capital Partners first reported a position in NBIX in Q4 2015 and held it in 2 quarters. The position peaked at $3.17M in Q4 2015. 245 funds tracked by Wall St. Rank hold NBIX as of Q3 2016.

Acuta Capital Partners reported no remaining Neurocrine Biosciences position as of Q3 2016 after selling out during the quarter.
Acuta Capital Partners sold 42,000 Neurocrine Biosciences shares in Q3 2016, an estimated $1.91M.
Acuta Capital Partners first reported a position in Neurocrine Biosciences in Q4 2015 and held it in 2 quarters.
Acuta Capital Partners's Neurocrine Biosciences position peaked at $3.17M in Q4 2015.
245 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2016.

Based on Acuta Capital Partners's 13F filing for Q3 2016, filed 14 Nov 2016.